Skip to content

L-Carnosine in the treatment of OCD

L-Carnosine as adjuvant therapy in the treatment of moderate to severe OCD: a double blind randomized trial with placebo control

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201604201556N88
Enrollment
50
Registered
2016-04-21
Start date
2016-05-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive- Cumpulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Fluvoxamine 100 mg/day+ L-Carnosine 500mg/day for 10 weeks as intervention group. Intervention 2: Fluvoxamine 100 mg/day + placebo for 10 weeks as control group.
Treatment - Drugs
Placebo
Fluvoxamine 100 mg/day+ L-Carnosine 500mg/day for 10 weeks as intervention group

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1-Age between 18-60years old; 2-Diagnosis of OCD based on DSM V; 3- Minimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale. Exclusion Criteria: 1- Substance dependence; 2- IQ <70; 3- Any other mental disorder on axis I; 4-Any serious cardiac, renal or hepatic disease; 5- receiving psychotropic medications during the last 6 weeks; 6- pregnancy or breast feeding; 7- Rising liver transaminases to three times the upper limit of normal or higher.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of symptoms of OCD. Timepoint: Baseline and weeks: 2, 4, 6, 8, 10 after beginig of treatment. Method of measurement: Y_BOCS( Yale-Brown obsessive compulsive scale).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

S.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026